At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 171 enrolled
Drug / intervention
BTL TML HSV +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Parallel, Placebo-controlled Study for the Assessment of the Safety and Efficacy of BTL-TML-HSV for the Treatment of Recurrent Symptomatic Oral Herpes Virus Infection
In Brief
A Phase 2 clinical trial evaluating BTL TML HSV and Matching placebo for Oral Herpes Simplex. Completed, enrolled 171 participants across 4 sites.
Detailed Summary
The purpose of this study is to determine if a new treatment is effective for the treatment of recurrent symptomatic oral herpes virus infections.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOral Herpes Simplex
CountriesUnited States
CollaboratorsNorwich Clinical Research Associates Ltd.
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedMar 2011
Primary CompletionOct 2012
Study CompletionNov 2012
TodayJul 2026
First PostedMar 4, 2011
Enrollment StartJan 1, 2011
Primary CompletionOct 1, 2012
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 15.3 years ago
Interventions
BTL TML HSVdrug
Sublingual micro-dosing for 7 days
Matching placebodrug
sublingual dosing for 7 days